Merck cervical cancer shot gives 5-year protection

	Tweet

An experimental vaccine from Merck & Co Inc designed to protect women against a virus that causes cervical cancer has proved effective for up to five years, researchers said on Wednesday.

Women given Gardasil, which Merck is developing with France’s Sanofi-Aventis, experienced no cases of cervical and external genital lesions, the precursors of cancer, scientists told a medical meeting in Paris.

Gardasil is set to compete with GlaxoSmithKline Plc’s rival vaccine Cervarix in what industry analysts expect to be a multibillion-dollar market.

Researchers backed by Glaxo earlier this month reported that women given Cervarix had protection for up to 4-1/2 years.

Both products protect against the human papillomavirus (HPV), a sexually transmitted infection that causes most cases of cervical cancer, the second-most fatal cancer in women.

Gardasil has already been filed for European and U.S. marketing approval, while Glaxo aims to submit Cervarix in the United States before the end of 2006, after filing in Europe last month.

Glaxo estimates the market opportunity for the new vaccines will be 2 billion pounds ($3.57 billion) to 4 billion pounds ($7.14 billion) a year by 2010.

RELATED STORIES:
Obese women in Canada are less likely to be screened for cervical cancer   Screening for cervical cancer low for immigrant women   Cervical disease sufferers could benefit from HPV vaccine   Staging of cervical cancer complicating pregnancy   Risk of cervical and other cancers after treatment of cervical intraepithelial neoplasia   HPV tests better for cervical screening - experts   Couples more likely to divorce if spouse develops cervical or testicular cancer   Vaccines alliance nears deal on cervical cancer shots   Optimal Treatment and Minimal Complications in Cervical Cancer Patients   Cervical cancer screening rates low in poor areas   The Pill doesn’t affect cervical pre-cancer risk   Cervical cancer drops, but disparities persist   High cervical cancer rates sign of larger problems   Cervical cancer risk higher in women on the pill   High HPV Concentrations, Smoking Significantly Raise Risks of Cancer   Health groups issue proposed cervical cancer screening guidelines   15 Common Myths About Cervical Cancer   Genetic Differences Help Protect Against Cervical Cancer   Cervical cancer vaccine can protect men from HPV   Girls should get cervical cancer vaccine, panel says   Aspirin Merits Testing for Prevention of Cervical Cancer in HIV-Infected Women   HPV testing: Indications of a benefit in primary screening

Comments

[ + Post Your Own ]

Now you're in the public comment zone. What follows is not Armenian Medical Network's stuff; it comes from other people and we don't vouch for it. A reminder: By using this Web site you agree to accept our Terms of Service. Click here to read the Rules of Engagement.

There are no comments for this entry yet. [ + Comment here + ]